On June 6th, Glonhui reported that Beijing Science Sun Pharmaceutical (300485.SZ), the leading product of the company is bio-chemical pharmaceuticals, involving three major areas of medication: cardiovascular and cerebrovascular diseases, immunological diseases (anti-tumor), and neurological disorders. The company is the national drug standard drafting unit for five varieties of products: fibrolysin, fibrolysin injection, injection of fibrolysin, thymosin alpha-1 for injection, and deoxyribonucleic sodium injection. Fibrolysin injection, thymosin alpha-1 for injection, deoxyribonucleic sodium injection, and 100mg injection for thymosin are the first drugs produced in the country; GM-1 ganglioside sodium injection and thymosin alpha-1 injection are national key new products; Fibrolysin, fibrolysin injection, injection of fibrolysin, large-scale injection of thymosin alpha-1 were rated as Beijing's independently innovated products, and the fibrolysin injection was rated as the excellent brand of biochemical and biological enterprises of the year 2023. Currently, the sales of the company's main products have declined compared to the previous year due to market and policy influences.
赛升药业(300485.SZ)：主导产品为生物生化药品，涉及心脑血管类疾病、 免疫性疾病（抗肿瘤）和神经系统疾病三大用药领域
Beijing Science Sun Pharmaceutical (300485.SZ): The main products are biopharmaceuticals, involving three major fields of medication for cardiovascular diseases, immune diseases (anti-tumor) and nervous system diseases.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.